HC Wainwright Reaffirms Buy Rating for Werewolf Therapeutics (NASDAQ:HOWL)
HC Wainwright reiterated their buy rating on shares of Werewolf Therapeutics (NASDAQ:HOWL – Free Report) in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $15 ...
Werewolf Therapeutics’ (HOWL) “Outperform” Rating Reiterated at Wedbush
Wedbush reissued their outperform rating on shares of Werewolf Therapeutics (NASDAQ:HOWL – Free Report) in a report issued on Wednesday morning, Marketbeat Ratings reports. They currently have a $8.00 ...